Drug Trial News

RSS

Hydroxychloroquine not able to prevent development of COVID-19, UMN trial shows

Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

4 Jun 2020

World’s first study of potential antibody therapy to fight COVID-19 begins in humans

Eli Lilly and Company today announced patients have been dosed in the world’s first study of a potential antibody treatment designed to fight COVID-19.

4 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.

3 Jun 2020

Octapharma extends support for COVID-19 study following promising preliminary data

Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.

3 Jun 2020

Study shows Sofosbuvir alleviates COVID-19-related neurological symptoms

A group of researchers has studied the effects of an antiviral drug Sofosbuvir on human brain organoids infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Jun 2020

Digital technology helps maintain clinical research operations during COVID-19 pandemic

As the COVID-19 pandemic has disrupted many routine medical services and discretionary surgical procedures, little attention has been paid to its impact on clinical research.

2 Jun 2020

Preliminary report of Favipiravir Observational Study in Japan released

Favipiravir Observational Study Group (principal investigator: Dr. Yohei Doi, Fujita Health University) released a preliminary report of the Favipiravir Observational Study in Japan on the Japanese Association for Infectious Diseases website.

2 Jun 2020

Lancet issues correction on paper than prompted WHO to suspend Hydroxychloroquine trial

The World Health Organization (WHO) suspended the hydroxychloroquine trial amid the coronavirus pandemic. The decision comes after the study findings published in The Lancet reported issues on the drug's efficacy and safety. Now, the journal has issued a correction on the figures reported in the study.

2 Jun 2020

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

The Austrian Breast & Colorectal Cancer Study Group, Alliance Foundation Trials, the Breast International Group, PrECOG, LLC, the German Breast Group, and the NSABP Foundation today announced that the independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study trial determined that the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival following a preplanned interim analysis.

1 Jun 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

30 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020

5-day Remdesivir dose works as well as the 10-day dose in COVID-19, study finds

With more than 5.8 million people infected with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search is on for an effective SARS-CoV-2 vaccine or drug to treat COVID-19 disease.

28 May 2020

Previous
1
...
76
77
78
79
80
81
82
...
1143
Next

Drug Trial News

Hydroxychloroquine not able to prevent development of COVID-19, UMN trial shows

World’s first study of potential antibody therapy to fight COVID-19 begins in humans

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Octapharma extends support for COVID-19 study following promising preliminary data

Study shows Sofosbuvir alleviates COVID-19-related neurological symptoms

Digital technology helps maintain clinical research operations during COVID-19 pandemic

Preliminary report of Favipiravir Observational Study in Japan released

Lancet issues correction on paper than prompted WHO to suspend Hydroxychloroquine trial

Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

5-day Remdesivir dose works as well as the 10-day dose in COVID-19, study finds

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News